发布求助
文献互助 智能选刊 最新文献

ACS Medicinal Chemistry Letters最新文献

筛选
英文 中文
In This Issue, Volume 16, Issue 2
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-02-13 DOI: 10.1021/acsmedchemlett.5c0002710.1021/acsmedchemlett.5c00027
John G. Woodland, 
{"title":"In This Issue, Volume 16, Issue 2","authors":"John G. Woodland, ","doi":"10.1021/acsmedchemlett.5c0002710.1021/acsmedchemlett.5c00027","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00027https://doi.org/10.1021/acsmedchemlett.5c00027","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"176–177 176–177"},"PeriodicalIF":3.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special Issue: Exploring the Use of AI/ML Technologies in Medicinal Chemistry and Drug Discovery
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-02-04 DOI: 10.1021/acsmedchemlett.5c0000310.1021/acsmedchemlett.5c00003
Sun Choi, Ashley M. Adams and Kelly Chibale*, 
{"title":"Special Issue: Exploring the Use of AI/ML Technologies in Medicinal Chemistry and Drug Discovery","authors":"Sun Choi, Ashley M. Adams and Kelly Chibale*, ","doi":"10.1021/acsmedchemlett.5c0000310.1021/acsmedchemlett.5c00003","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00003https://doi.org/10.1021/acsmedchemlett.5c00003","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"174 174"},"PeriodicalIF":3.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special Issue: Exploring the Use of AI/ML Technologies in Medicinal Chemistry and Drug Discovery.
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-02-04 eCollection Date: 2025-02-13 DOI: 10.1021/acsmedchemlett.5c00003
Sun Choi, Ashley M Adams, Kelly Chibale
{"title":"Special Issue: Exploring the Use of AI/ML Technologies in Medicinal Chemistry and Drug Discovery.","authors":"Sun Choi, Ashley M Adams, Kelly Chibale","doi":"10.1021/acsmedchemlett.5c00003","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00003","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"174"},"PeriodicalIF":3.5,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Chemistry Reviews, Volume 59
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-31 DOI: 10.1021/acsmedchemlett.5c0003610.1021/acsmedchemlett.5c00036
Joachim Rudolph*,  and , William J. Watkins*, 
{"title":"Medicinal Chemistry Reviews, Volume 59","authors":"Joachim Rudolph*,  and , William J. Watkins*, ","doi":"10.1021/acsmedchemlett.5c0003610.1021/acsmedchemlett.5c00036","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00036https://doi.org/10.1021/acsmedchemlett.5c00036","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"175 175"},"PeriodicalIF":3.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Chemistry Reviews, Volume 59.
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-31 eCollection Date: 2025-02-13 DOI: 10.1021/acsmedchemlett.5c00036
Joachim Rudolph, William J Watkins
{"title":"<i>Medicinal Chemistry Reviews</i>, Volume 59.","authors":"Joachim Rudolph, William J Watkins","doi":"10.1021/acsmedchemlett.5c00036","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00036","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"175"},"PeriodicalIF":3.5,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics.
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 eCollection Date: 2025-02-13 DOI: 10.1021/acsmedchemlett.5c00028
Robert B Kargbo
{"title":"Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics.","authors":"Robert B Kargbo","doi":"10.1021/acsmedchemlett.5c00028","DOIUrl":"10.1021/acsmedchemlett.5c00028","url":null,"abstract":"<p><p>Researchers have long recognized RAS mutations as one of the most challenging targets in oncology. These genetic alterations are central drivers of tumor progression in cancers such as melanoma, colorectal cancer, and pancreatic adenocarcinoma. The recent advancements described in patent applications WO 2024/243186 A2 and WO 2024/246099 A1 introduce two novel classes of inhibitors: heterocyclic compounds targeting NRAS G12D and spirocyclic derivatives directed at KRAS mutations, including G12C, G12D, and G12 V. These compounds, a fresh and innovative approach, disrupt critical RAS-dependent signaling pathways, offering a pathway to mitigate tumor growth and overcome resistance to standard therapies. This Patent Highlight explores their mechanisms, preclinical successes, and implications for future cancer treatment strategies.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"216-218"},"PeriodicalIF":3.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative Protein Degraders for Targeted Cancer and Viral Therapy
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 DOI: 10.1021/acsmedchemlett.5c0003010.1021/acsmedchemlett.5c00030
Robert B. Kargbo*, 
{"title":"Innovative Protein Degraders for Targeted Cancer and Viral Therapy","authors":"Robert B. Kargbo*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0003010.1021/acsmedchemlett.5c00030","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00030https://doi.org/10.1021/acsmedchemlett.5c00030","url":null,"abstract":"<p >The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, and substituted oxazolone compounds targeting IKZF1–4 transcription factors. These compounds demonstrate exceptional efficacy in degrading pathogenic proteins, reprogramming immune responses, and facilitating tumor immunity. This dual approach underscores the potential of cellular degradation systems in precision medicine.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"222–223 222–223"},"PeriodicalIF":3.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 eCollection Date: 2025-02-13 DOI: 10.1021/acsmedchemlett.5c00031
Robert B Kargbo
{"title":"Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.","authors":"Robert B Kargbo","doi":"10.1021/acsmedchemlett.5c00031","DOIUrl":"10.1021/acsmedchemlett.5c00031","url":null,"abstract":"<p><p>Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors (SSRIs) with short-acting psychedelics, such as <i>N</i>,<i>N</i>-dimethyltryptamine (DMT) and psilocybin, provides rapid and sustained improvements in treatment-resistant depression and anxiety. Meanwhile, AI-enhanced behavioral monitoring leverages motion tracking and machine learning to quantify treatment outcomes in animal models, accelerating drug development. Together, these approaches redefine therapeutic paradigms, offering personalized and effective treatments for psychiatric disorders.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"219-221"},"PeriodicalIF":3.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 DOI: 10.1021/acsmedchemlett.5c0003110.1021/acsmedchemlett.5c00031
Robert B. Kargbo*, 
{"title":"Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring","authors":"Robert B. Kargbo*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0003110.1021/acsmedchemlett.5c00031","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00031https://doi.org/10.1021/acsmedchemlett.5c00031","url":null,"abstract":"<p >Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors (SSRIs) with short-acting psychedelics, such as <i>N</i>,<i>N</i>-dimethyltryptamine (DMT) and psilocybin, provides rapid and sustained improvements in treatment-resistant depression and anxiety. Meanwhile, AI-enhanced behavioral monitoring leverages motion tracking and machine learning to quantify treatment outcomes in animal models, accelerating drug development. Together, these approaches redefine therapeutic paradigms, offering personalized and effective treatments for psychiatric disorders.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"219–221 219–221"},"PeriodicalIF":3.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics
IF 3.5 3区 医学
ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 DOI: 10.1021/acsmedchemlett.5c0002810.1021/acsmedchemlett.5c00028
Robert B. Kargbo*, 
{"title":"Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics","authors":"Robert B. Kargbo*,&nbsp;","doi":"10.1021/acsmedchemlett.5c0002810.1021/acsmedchemlett.5c00028","DOIUrl":"https://doi.org/10.1021/acsmedchemlett.5c00028https://doi.org/10.1021/acsmedchemlett.5c00028","url":null,"abstract":"<p >Researchers have long recognized RAS mutations as one of the most challenging targets in oncology. These genetic alterations are central drivers of tumor progression in cancers such as melanoma, colorectal cancer, and pancreatic adenocarcinoma. The recent advancements described in patent applications WO 2024/243186 A2 and WO 2024/246099 A1 introduce two novel classes of inhibitors: heterocyclic compounds targeting NRAS G12D and spirocyclic derivatives directed at KRAS mutations, including G12C, G12D, and G12 V. These compounds, a fresh and innovative approach, disrupt critical RAS-dependent signaling pathways, offering a pathway to mitigate tumor growth and overcome resistance to standard therapies. This Patent Highlight explores their mechanisms, preclinical successes, and implications for future cancer treatment strategies.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"216–218 216–218"},"PeriodicalIF":3.5,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143394272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信